nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Bladder spasm—Furosemide—dilated cardiomyopathy	0.0326	0.0495	CcSEcCtD
Everolimus—Hydronephrosis—Furosemide—dilated cardiomyopathy	0.0214	0.0324	CcSEcCtD
Everolimus—Breast cancer—Spironolactone—dilated cardiomyopathy	0.0206	0.0313	CcSEcCtD
Everolimus—Hypertrichosis—Spironolactone—dilated cardiomyopathy	0.0198	0.03	CcSEcCtD
Everolimus—MTOR—LKB1 signaling events—SIK1—dilated cardiomyopathy	0.0177	0.0519	CbGpPWpGaD
Everolimus—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.0136	0.0206	CcSEcCtD
Everolimus—MTOR—S6K1-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.011	0.0323	CbGpPWpGaD
Everolimus—Blood cholesterol increased—Furosemide—dilated cardiomyopathy	0.0102	0.0154	CcSEcCtD
Everolimus—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.00982	0.0149	CcSEcCtD
Everolimus—MTOR—mTORC1-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.00937	0.0275	CbGpPWpGaD
Everolimus—Pancreatitis acute—Furosemide—dilated cardiomyopathy	0.00887	0.0135	CcSEcCtD
Everolimus—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00856	0.013	CcSEcCtD
Everolimus—Pyelonephritis—Lisinopril—dilated cardiomyopathy	0.00808	0.0123	CcSEcCtD
Everolimus—Epigastric discomfort—Furosemide—dilated cardiomyopathy	0.00778	0.0118	CcSEcCtD
Everolimus—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00739	0.0112	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NPPB—dilated cardiomyopathy	0.00739	0.0217	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—FASLG—dilated cardiomyopathy	0.00733	0.0215	CbGpPWpGaD
Everolimus—Lung infiltration—Lisinopril—dilated cardiomyopathy	0.00655	0.00994	CcSEcCtD
Everolimus—FKBP1A—TOR Signaling—RPS6KB1—dilated cardiomyopathy	0.00646	0.0189	CbGpPWpGaD
Everolimus—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00644	0.00978	CcSEcCtD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00629	0.0185	CbGpPWpGaD
Everolimus—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00625	0.00948	CcSEcCtD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00612	0.0179	CbGpPWpGaD
Everolimus—Nephritis interstitial—Furosemide—dilated cardiomyopathy	0.00606	0.0092	CcSEcCtD
Everolimus—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00592	0.00898	CcSEcCtD
Everolimus—FKBP1A—TOR Signaling—RAC1—dilated cardiomyopathy	0.00583	0.0171	CbGpPWpGaD
Everolimus—Thrombosis—Furosemide—dilated cardiomyopathy	0.00578	0.00878	CcSEcCtD
Everolimus—Azotaemia—Lisinopril—dilated cardiomyopathy	0.00576	0.00875	CcSEcCtD
Everolimus—MTOR—LKB1 signaling events—PSEN2—dilated cardiomyopathy	0.00566	0.0166	CbGpPWpGaD
Everolimus—Lethargy—Spironolactone—dilated cardiomyopathy	0.00557	0.00846	CcSEcCtD
Everolimus—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.00535	0.00811	CcSEcCtD
Everolimus—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00516	0.00784	CcSEcCtD
Everolimus—MTOR—CXCR3-mediated signaling events—CXCR3—dilated cardiomyopathy	0.00516	0.0151	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00502	0.0147	CbGpPWpGaD
Everolimus—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00499	0.00758	CcSEcCtD
Everolimus—Gastritis—Spironolactone—dilated cardiomyopathy	0.00483	0.00733	CcSEcCtD
Everolimus—FKBP1A—TGF-beta receptor signaling—RPS6KB1—dilated cardiomyopathy	0.00481	0.0141	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—NPPA—dilated cardiomyopathy	0.0048	0.0141	CbGpPWpGaD
Everolimus—MTOR—mTOR signalling—RPS6KB1—dilated cardiomyopathy	0.00457	0.0134	CbGpPWpGaD
Everolimus—MTOR—FSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00457	0.0134	CbGpPWpGaD
Everolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—dilated cardiomyopathy	0.00452	0.0133	CbGpPWpGaD
Everolimus—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00447	0.00679	CcSEcCtD
Everolimus—MTOR—PKB-mediated events—RPS6KB1—dilated cardiomyopathy	0.00444	0.013	CbGpPWpGaD
Everolimus—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00441	0.0067	CcSEcCtD
Everolimus—Gout—Furosemide—dilated cardiomyopathy	0.00438	0.00665	CcSEcCtD
Everolimus—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00435	0.0066	CcSEcCtD
Everolimus—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00426	0.00647	CcSEcCtD
Everolimus—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00417	0.00633	CcSEcCtD
Everolimus—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00415	0.0063	CcSEcCtD
Everolimus—Renal failure—Spironolactone—dilated cardiomyopathy	0.00414	0.00628	CcSEcCtD
Everolimus—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00408	0.00619	CcSEcCtD
Everolimus—MTOR—VEGFR2 mediated vascular permeability—RAC1—dilated cardiomyopathy	0.00401	0.0118	CbGpPWpGaD
Everolimus—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00401	0.00609	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00398	0.0117	CbGpPWpGaD
Everolimus—Otitis media—Lisinopril—dilated cardiomyopathy	0.00394	0.00599	CcSEcCtD
Everolimus—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00379	0.00575	CcSEcCtD
Everolimus—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.0037	0.00562	CcSEcCtD
Everolimus—Urine output increased—Furosemide—dilated cardiomyopathy	0.0037	0.00562	CcSEcCtD
Everolimus—Bladder pain—Furosemide—dilated cardiomyopathy	0.0037	0.00562	CcSEcCtD
Everolimus—MTOR—TOR Signaling—RPS6KB1—dilated cardiomyopathy	0.00363	0.0106	CbGpPWpGaD
Everolimus—MTOR—CD28 co-stimulation—RAC1—dilated cardiomyopathy	0.0036	0.0106	CbGpPWpGaD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—RPS6KB1—dilated cardiomyopathy	0.00355	0.0104	CbGpPWpGaD
Everolimus—MTOR—Alpha 6 Beta 4 signaling pathway—RAC1—dilated cardiomyopathy	0.00352	0.0103	CbGpPWpGaD
Everolimus—Proteinuria—Lisinopril—dilated cardiomyopathy	0.0035	0.0053	CcSEcCtD
Everolimus—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00347	0.00527	CcSEcCtD
Everolimus—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00345	0.00523	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NPPA—dilated cardiomyopathy	0.00342	0.01	CbGpPWpGaD
Everolimus—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00342	0.00518	CcSEcCtD
Everolimus—Viral infection—Lisinopril—dilated cardiomyopathy	0.0034	0.00516	CcSEcCtD
Everolimus—Polyuria—Furosemide—dilated cardiomyopathy	0.00338	0.00514	CcSEcCtD
Everolimus—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00338	0.00513	CcSEcCtD
Everolimus—Alopecia—Spironolactone—dilated cardiomyopathy	0.00334	0.00507	CcSEcCtD
Everolimus—Gout—Lisinopril—dilated cardiomyopathy	0.00329	0.00499	CcSEcCtD
Everolimus—MTOR—TOR Signaling—RAC1—dilated cardiomyopathy	0.00328	0.00962	CbGpPWpGaD
Everolimus—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00327	0.00496	CcSEcCtD
Everolimus—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00323	0.0049	CcSEcCtD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—RAC1—dilated cardiomyopathy	0.00321	0.00941	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—GJA1—dilated cardiomyopathy	0.00321	0.0094	CbGpPWpGaD
Everolimus—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00316	0.0048	CcSEcCtD
Everolimus—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00315	0.00478	CcSEcCtD
Everolimus—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00311	0.00472	CcSEcCtD
Everolimus—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00307	0.00466	CcSEcCtD
Everolimus—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00305	0.00463	CcSEcCtD
Everolimus—Lethargy—Furosemide—dilated cardiomyopathy	0.00303	0.0046	CcSEcCtD
Everolimus—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00302	0.00458	CcSEcCtD
Everolimus—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00298	0.00453	CcSEcCtD
Everolimus—Wheezing—Lisinopril—dilated cardiomyopathy	0.00298	0.00453	CcSEcCtD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.00298	0.00873	CbGpPWpGaD
Everolimus—Malaise—Spironolactone—dilated cardiomyopathy	0.00297	0.0045	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.00296	0.00868	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—RAC1—dilated cardiomyopathy	0.00296	0.00867	CbGpPWpGaD
Everolimus—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00294	0.00447	CcSEcCtD
Everolimus—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00292	0.00442	CcSEcCtD
Everolimus—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.0029	0.0044	CcSEcCtD
Everolimus—Irritability—Furosemide—dilated cardiomyopathy	0.00284	0.0043	CcSEcCtD
Everolimus—Urinary retention—Furosemide—dilated cardiomyopathy	0.00283	0.00429	CcSEcCtD
Everolimus—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00278	0.00422	CcSEcCtD
Everolimus—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00278	0.00421	CcSEcCtD
Everolimus—Discomfort—Spironolactone—dilated cardiomyopathy	0.00277	0.0042	CcSEcCtD
Everolimus—Dehydration—Furosemide—dilated cardiomyopathy	0.00276	0.00419	CcSEcCtD
Everolimus—MTOR—FSH signaling pathway—RAF1—dilated cardiomyopathy	0.00274	0.00803	CbGpPWpGaD
Everolimus—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00273	0.00415	CcSEcCtD
Everolimus—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.0027	0.0041	CcSEcCtD
Everolimus—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00263	0.00399	CcSEcCtD
Everolimus—MTOR—Interferon type I signaling pathways—RPS6KB1—dilated cardiomyopathy	0.00262	0.0077	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00262	0.0077	CbGpPWpGaD
Everolimus—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00262	0.00398	CcSEcCtD
Everolimus—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00259	0.00392	CcSEcCtD
Everolimus—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00256	0.00389	CcSEcCtD
Everolimus—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00252	0.00382	CcSEcCtD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—RAF1—dilated cardiomyopathy	0.00252	0.00738	CbGpPWpGaD
Everolimus—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00252	0.00382	CcSEcCtD
Everolimus—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00248	0.00376	CcSEcCtD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.00246	0.0072	CbGpPWpGaD
Everolimus—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00245	0.00371	CcSEcCtD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—RAC1—dilated cardiomyopathy	0.00244	0.00717	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—IL10—dilated cardiomyopathy	0.00242	0.00708	CbGpPWpGaD
Everolimus—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00241	0.00366	CcSEcCtD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.00241	0.00707	CbGpPWpGaD
Everolimus—Somnolence—Spironolactone—dilated cardiomyopathy	0.00239	0.00362	CcSEcCtD
Everolimus—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00237	0.0036	CcSEcCtD
Everolimus—MTOR—Interferon type I signaling pathways—RAC1—dilated cardiomyopathy	0.00237	0.00695	CbGpPWpGaD
Everolimus—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00235	0.00357	CcSEcCtD
Everolimus—MTOR—IL4-mediated signaling events—RPS6KB1—dilated cardiomyopathy	0.00235	0.00689	CbGpPWpGaD
Everolimus—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00234	0.00355	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—RAC1—dilated cardiomyopathy	0.00234	0.00685	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00234	0.00685	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00232	0.00352	CcSEcCtD
Everolimus—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00232	0.00352	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—FASLG—dilated cardiomyopathy	0.00231	0.00676	CbGpPWpGaD
Everolimus—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00228	0.00347	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.00226	0.00662	CbGpPWpGaD
Everolimus—Renal failure—Furosemide—dilated cardiomyopathy	0.00225	0.00342	CcSEcCtD
Everolimus—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00224	0.0034	CcSEcCtD
Everolimus—MTOR—mTOR signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00224	0.00655	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00224	0.00655	CbGpPWpGaD
Everolimus—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00223	0.00338	CcSEcCtD
Everolimus—MTOR—Class I PI3K signaling events mediated by Akt—RAF1—dilated cardiomyopathy	0.00222	0.00652	CbGpPWpGaD
Everolimus—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00221	0.00336	CcSEcCtD
Everolimus—MTOR—PI3K Cascade—RPS6KB1—dilated cardiomyopathy	0.00218	0.0064	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—RPS6KB1—dilated cardiomyopathy	0.00218	0.0064	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00217	0.00329	CcSEcCtD
Everolimus—MTOR—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00216	0.00633	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—RPS6KB1—dilated cardiomyopathy	0.00213	0.00625	CbGpPWpGaD
Everolimus—Irritability—Lisinopril—dilated cardiomyopathy	0.00213	0.00323	CcSEcCtD
Everolimus—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00212	0.00322	CcSEcCtD
Everolimus—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00212	0.00322	CcSEcCtD
Everolimus—MTOR—Type II diabetes mellitus—TNF—dilated cardiomyopathy	0.00211	0.00618	CbGpPWpGaD
Everolimus—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00209	0.00317	CcSEcCtD
Everolimus—MTOR—CXCR3-mediated signaling events—RAF1—dilated cardiomyopathy	0.00208	0.00611	CbGpPWpGaD
Everolimus—Dehydration—Lisinopril—dilated cardiomyopathy	0.00207	0.00315	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.00206	0.00604	CbGpPWpGaD
Everolimus—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00203	0.00308	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00202	0.00592	CbGpPWpGaD
Everolimus—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00201	0.00306	CcSEcCtD
Everolimus—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00201	0.00306	CcSEcCtD
Everolimus—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00199	0.00303	CcSEcCtD
Everolimus—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00198	0.003	CcSEcCtD
Everolimus—Gastritis—Lisinopril—dilated cardiomyopathy	0.00197	0.00299	CcSEcCtD
Everolimus—MTOR—Costimulation by the CD28 family—RAC1—dilated cardiomyopathy	0.00197	0.00578	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—RAF1—dilated cardiomyopathy	0.00196	0.00575	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—RAC1—dilated cardiomyopathy	0.00193	0.00565	CbGpPWpGaD
Everolimus—Influenza—Lisinopril—dilated cardiomyopathy	0.00193	0.00292	CcSEcCtD
Everolimus—Eye disorder—Furosemide—dilated cardiomyopathy	0.00192	0.00292	CcSEcCtD
Everolimus—Pruritus—Spironolactone—dilated cardiomyopathy	0.0019	0.00288	CcSEcCtD
Everolimus—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.0019	0.00288	CcSEcCtD
Everolimus—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00189	0.00287	CcSEcCtD
Everolimus—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00188	0.00285	CcSEcCtD
Everolimus—Angiopathy—Furosemide—dilated cardiomyopathy	0.00186	0.00283	CcSEcCtD
Everolimus—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00186	0.00282	CcSEcCtD
Everolimus—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00185	0.00281	CcSEcCtD
Everolimus—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00184	0.00279	CcSEcCtD
Everolimus—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00183	0.00278	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—dilated cardiomyopathy	0.00183	0.00535	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.00183	0.00535	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.00182	0.00535	CbGpPWpGaD
Everolimus—Dysuria—Lisinopril—dilated cardiomyopathy	0.0018	0.00273	CcSEcCtD
Everolimus—Neutropenia—Lisinopril—dilated cardiomyopathy	0.0018	0.00273	CcSEcCtD
Everolimus—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00179	0.00272	CcSEcCtD
Everolimus—Malnutrition—Furosemide—dilated cardiomyopathy	0.00179	0.00272	CcSEcCtD
Everolimus—Erythema—Furosemide—dilated cardiomyopathy	0.00179	0.00272	CcSEcCtD
Everolimus—MTOR—IRS-related events—RPS6KB1—dilated cardiomyopathy	0.00178	0.00521	CbGpPWpGaD
Everolimus—Dizziness—Spironolactone—dilated cardiomyopathy	0.00178	0.00269	CcSEcCtD
Everolimus—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00177	0.00269	CcSEcCtD
Everolimus—Flatulence—Furosemide—dilated cardiomyopathy	0.00176	0.00268	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—RPS6KB1—dilated cardiomyopathy	0.00176	0.00516	CbGpPWpGaD
Everolimus—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00175	0.00266	CcSEcCtD
Everolimus—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00174	0.00265	CcSEcCtD
Everolimus—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00174	0.00264	CcSEcCtD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAC1—dilated cardiomyopathy	0.00173	0.00508	CbGpPWpGaD
Everolimus—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00173	0.00262	CcSEcCtD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—dilated cardiomyopathy	0.00173	0.00506	CbGpPWpGaD
Everolimus—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00172	0.00261	CcSEcCtD
Everolimus—MTOR—IGF1R signaling cascade—RPS6KB1—dilated cardiomyopathy	0.00171	0.00503	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—RPS6KB1—dilated cardiomyopathy	0.00171	0.00503	CbGpPWpGaD
Everolimus—Vomiting—Spironolactone—dilated cardiomyopathy	0.00171	0.00259	CcSEcCtD
Everolimus—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00169	0.00257	CcSEcCtD
Everolimus—Rash—Spironolactone—dilated cardiomyopathy	0.00169	0.00257	CcSEcCtD
Everolimus—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00169	0.00257	CcSEcCtD
Everolimus—Renal failure—Lisinopril—dilated cardiomyopathy	0.00169	0.00256	CcSEcCtD
Everolimus—Vision blurred—Furosemide—dilated cardiomyopathy	0.00169	0.00256	CcSEcCtD
Everolimus—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00168	0.00256	CcSEcCtD
Everolimus—Headache—Spironolactone—dilated cardiomyopathy	0.00168	0.00255	CcSEcCtD
Everolimus—Jaundice—Lisinopril—dilated cardiomyopathy	0.00167	0.00254	CcSEcCtD
Everolimus—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00167	0.00253	CcSEcCtD
Everolimus—MTOR—CXCR4-mediated signaling events—RAC1—dilated cardiomyopathy	0.00167	0.00488	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAC1—dilated cardiomyopathy	0.00167	0.00488	CbGpPWpGaD
Everolimus—Anaemia—Furosemide—dilated cardiomyopathy	0.00165	0.00251	CcSEcCtD
Everolimus—Agitation—Furosemide—dilated cardiomyopathy	0.00164	0.0025	CcSEcCtD
Everolimus—Haematuria—Lisinopril—dilated cardiomyopathy	0.00164	0.00249	CcSEcCtD
Everolimus—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00162	0.00247	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00162	0.00476	CbGpPWpGaD
Everolimus—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00162	0.00246	CcSEcCtD
Everolimus—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00161	0.00245	CcSEcCtD
Everolimus—Leukopenia—Furosemide—dilated cardiomyopathy	0.0016	0.00243	CcSEcCtD
Everolimus—Nausea—Spironolactone—dilated cardiomyopathy	0.00159	0.00242	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AGT—dilated cardiomyopathy	0.00159	0.00467	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00157	0.00459	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—RAF1—dilated cardiomyopathy	0.00155	0.00454	CbGpPWpGaD
Everolimus—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00155	0.00235	CcSEcCtD
Everolimus—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00154	0.00234	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00153	0.0045	CbGpPWpGaD
Everolimus—Hallucination—Lisinopril—dilated cardiomyopathy	0.00153	0.00233	CcSEcCtD
Everolimus—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00153	0.00232	CcSEcCtD
Everolimus—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00152	0.00231	CcSEcCtD
Everolimus—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00152	0.00231	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00151	0.0023	CcSEcCtD
Everolimus—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00151	0.00229	CcSEcCtD
Everolimus—Dry mouth—Furosemide—dilated cardiomyopathy	0.00149	0.00226	CcSEcCtD
Everolimus—Shock—Furosemide—dilated cardiomyopathy	0.00144	0.00218	CcSEcCtD
Everolimus—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00143	0.00217	CcSEcCtD
Everolimus—Flushing—Lisinopril—dilated cardiomyopathy	0.00143	0.00217	CcSEcCtD
Everolimus—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00143	0.00217	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—RPS6KB1—dilated cardiomyopathy	0.00142	0.00417	CbGpPWpGaD
Everolimus—Skin disorder—Furosemide—dilated cardiomyopathy	0.00142	0.00215	CcSEcCtD
Everolimus—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00141	0.00214	CcSEcCtD
Everolimus—Angiopathy—Lisinopril—dilated cardiomyopathy	0.0014	0.00212	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—RAC1—dilated cardiomyopathy	0.00139	0.00408	CbGpPWpGaD
Everolimus—Anorexia—Furosemide—dilated cardiomyopathy	0.00139	0.00211	CcSEcCtD
Everolimus—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00139	0.00211	CcSEcCtD
Everolimus—Chills—Lisinopril—dilated cardiomyopathy	0.00138	0.0021	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—RAC1—dilated cardiomyopathy	0.00137	0.00402	CbGpPWpGaD
Everolimus—Hypotension—Furosemide—dilated cardiomyopathy	0.00136	0.00207	CcSEcCtD
Everolimus—Alopecia—Lisinopril—dilated cardiomyopathy	0.00136	0.00207	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—RAF1—dilated cardiomyopathy	0.00136	0.00398	CbGpPWpGaD
Everolimus—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00135	0.00205	CcSEcCtD
Everolimus—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00134	0.00204	CcSEcCtD
Everolimus—Erythema—Lisinopril—dilated cardiomyopathy	0.00134	0.00204	CcSEcCtD
Everolimus—MTOR—mTOR signaling pathway—RAF1—dilated cardiomyopathy	0.00134	0.00393	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—RAF1—dilated cardiomyopathy	0.00134	0.00393	CbGpPWpGaD
Everolimus—Flatulence—Lisinopril—dilated cardiomyopathy	0.00132	0.00201	CcSEcCtD
Everolimus—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00131	0.002	CcSEcCtD
Everolimus—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00131	0.00199	CcSEcCtD
Everolimus—Back pain—Lisinopril—dilated cardiomyopathy	0.0013	0.00197	CcSEcCtD
Everolimus—Somnolence—Furosemide—dilated cardiomyopathy	0.0013	0.00197	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—RAC1—dilated cardiomyopathy	0.0013	0.0038	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.00129	0.00379	CbGpPWpGaD
Everolimus—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00129	0.00196	CcSEcCtD
Everolimus—MTOR—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.00128	0.00375	CbGpPWpGaD
Everolimus—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00127	0.00193	CcSEcCtD
Everolimus—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00127	0.00192	CcSEcCtD
Everolimus—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00126	0.00191	CcSEcCtD
Everolimus—Fatigue—Furosemide—dilated cardiomyopathy	0.00126	0.00191	CcSEcCtD
Everolimus—Tremor—Lisinopril—dilated cardiomyopathy	0.00126	0.00191	CcSEcCtD
Everolimus—Pain—Furosemide—dilated cardiomyopathy	0.00125	0.0019	CcSEcCtD
Everolimus—Constipation—Furosemide—dilated cardiomyopathy	0.00125	0.0019	CcSEcCtD
Everolimus—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00125	0.00189	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.00124	0.00364	CbGpPWpGaD
Everolimus—Anaemia—Lisinopril—dilated cardiomyopathy	0.00124	0.00188	CcSEcCtD
Everolimus—Angioedema—Lisinopril—dilated cardiomyopathy	0.00123	0.00186	CcSEcCtD
Everolimus—Malaise—Lisinopril—dilated cardiomyopathy	0.00121	0.00184	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.00121	0.00355	CbGpPWpGaD
Everolimus—Syncope—Lisinopril—dilated cardiomyopathy	0.0012	0.00183	CcSEcCtD
Everolimus—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.0012	0.00183	CcSEcCtD
Everolimus—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0012	0.00182	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.0012	0.00351	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00119	0.00181	CcSEcCtD
Everolimus—Palpitations—Lisinopril—dilated cardiomyopathy	0.00119	0.0018	CcSEcCtD
Everolimus—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00118	0.00179	CcSEcCtD
Everolimus—Cough—Lisinopril—dilated cardiomyopathy	0.00117	0.00178	CcSEcCtD
Everolimus—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00115	0.00175	CcSEcCtD
Everolimus—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00115	0.00175	CcSEcCtD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAF1—dilated cardiomyopathy	0.00115	0.00337	CbGpPWpGaD
Everolimus—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00114	0.00173	CcSEcCtD
Everolimus—Myalgia—Lisinopril—dilated cardiomyopathy	0.00114	0.00173	CcSEcCtD
Everolimus—Chest pain—Lisinopril—dilated cardiomyopathy	0.00114	0.00173	CcSEcCtD
Everolimus—Anxiety—Lisinopril—dilated cardiomyopathy	0.00114	0.00173	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00114	0.00172	CcSEcCtD
Everolimus—Discomfort—Lisinopril—dilated cardiomyopathy	0.00113	0.00171	CcSEcCtD
Everolimus—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00112	0.0017	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.0011	0.00324	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.0011	0.00323	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.0011	0.00323	CbGpPWpGaD
Everolimus—Oedema—Lisinopril—dilated cardiomyopathy	0.0011	0.00166	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—RAF1—dilated cardiomyopathy	0.00109	0.00321	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00109	0.0032	CbGpPWpGaD
Everolimus—Infection—Lisinopril—dilated cardiomyopathy	0.00109	0.00165	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00108	0.00317	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—EGFR—dilated cardiomyopathy	0.00108	0.00316	CbGpPWpGaD
Everolimus—Shock—Lisinopril—dilated cardiomyopathy	0.00108	0.00164	CcSEcCtD
Everolimus—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00108	0.00163	CcSEcCtD
Everolimus—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00107	0.00163	CcSEcCtD
Everolimus—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00107	0.00162	CcSEcCtD
Everolimus—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00106	0.00162	CcSEcCtD
Everolimus—MTOR—IRS-related events—RAF1—dilated cardiomyopathy	0.00106	0.00312	CbGpPWpGaD
Everolimus—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00106	0.00161	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—RAF1—dilated cardiomyopathy	0.00105	0.00309	CbGpPWpGaD
Everolimus—Asthenia—Furosemide—dilated cardiomyopathy	0.00105	0.00159	CcSEcCtD
Everolimus—Anorexia—Lisinopril—dilated cardiomyopathy	0.00104	0.00159	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.00104	0.00305	CbGpPWpGaD
Everolimus—Pruritus—Furosemide—dilated cardiomyopathy	0.00103	0.00157	CcSEcCtD
Everolimus—MTOR—IGF1R signaling cascade—RAF1—dilated cardiomyopathy	0.00103	0.00301	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—RAF1—dilated cardiomyopathy	0.00103	0.00301	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.00103	0.00301	CbGpPWpGaD
Everolimus—Hypotension—Lisinopril—dilated cardiomyopathy	0.00102	0.00155	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.00102	0.00298	CbGpPWpGaD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.00101	0.00297	CbGpPWpGaD
Everolimus—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000999	0.00152	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000998	0.00151	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000995	0.00292	CbGpPWpGaD
Everolimus—Insomnia—Lisinopril—dilated cardiomyopathy	0.000991	0.0015	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000985	0.00289	CbGpPWpGaD
Everolimus—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000984	0.00149	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.000977	0.00286	CbGpPWpGaD
Everolimus—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000977	0.00148	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—RAC1—dilated cardiomyopathy	0.000975	0.00286	CbGpPWpGaD
Everolimus—Somnolence—Lisinopril—dilated cardiomyopathy	0.000974	0.00148	CcSEcCtD
Everolimus—Dizziness—Furosemide—dilated cardiomyopathy	0.000966	0.00147	CcSEcCtD
Everolimus—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000965	0.00146	CcSEcCtD
Everolimus—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000953	0.00145	CcSEcCtD
Everolimus—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000946	0.00144	CcSEcCtD
Everolimus—Fatigue—Lisinopril—dilated cardiomyopathy	0.000945	0.00143	CcSEcCtD
Everolimus—Constipation—Lisinopril—dilated cardiomyopathy	0.000937	0.00142	CcSEcCtD
Everolimus—Pain—Lisinopril—dilated cardiomyopathy	0.000937	0.00142	CcSEcCtD
Everolimus—Vomiting—Furosemide—dilated cardiomyopathy	0.000929	0.00141	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000924	0.00271	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000924	0.00271	CbGpPWpGaD
Everolimus—Rash—Furosemide—dilated cardiomyopathy	0.000921	0.0014	CcSEcCtD
Everolimus—Dermatitis—Furosemide—dilated cardiomyopathy	0.00092	0.0014	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000917	0.00269	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000917	0.00269	CbGpPWpGaD
Everolimus—Headache—Furosemide—dilated cardiomyopathy	0.000915	0.00139	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.00091	0.00267	CbGpPWpGaD
Everolimus—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000903	0.00137	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.000897	0.00263	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000896	0.00136	CcSEcCtD
Everolimus—Nausea—Furosemide—dilated cardiomyopathy	0.000867	0.00132	CcSEcCtD
Everolimus—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000866	0.00131	CcSEcCtD
Everolimus—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000866	0.00131	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000859	0.00252	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.000853	0.0025	CbGpPWpGaD
Everolimus—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000807	0.00123	CcSEcCtD
Everolimus—Asthenia—Lisinopril—dilated cardiomyopathy	0.000786	0.00119	CcSEcCtD
Everolimus—Pruritus—Lisinopril—dilated cardiomyopathy	0.000775	0.00118	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000761	0.00223	CbGpPWpGaD
Everolimus—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00075	0.00114	CcSEcCtD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000743	0.00218	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.00073	0.00214	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000726	0.00213	CbGpPWpGaD
Everolimus—Dizziness—Lisinopril—dilated cardiomyopathy	0.000725	0.0011	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000721	0.00211	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000717	0.0021	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NPPA—dilated cardiomyopathy	0.0007	0.00205	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000698	0.00205	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000698	0.00205	CbGpPWpGaD
Everolimus—Vomiting—Lisinopril—dilated cardiomyopathy	0.000697	0.00106	CcSEcCtD
Everolimus—Rash—Lisinopril—dilated cardiomyopathy	0.000691	0.00105	CcSEcCtD
Everolimus—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00069	0.00105	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000687	0.00201	CbGpPWpGaD
Everolimus—Headache—Lisinopril—dilated cardiomyopathy	0.000686	0.00104	CcSEcCtD
Everolimus—FKBP1A—Disease—PSEN2—dilated cardiomyopathy	0.000678	0.00199	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000669	0.00196	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000665	0.00195	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000659	0.00193	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000656	0.00192	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000653	0.00192	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000653	0.00191	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000653	0.00191	CbGpPWpGaD
Everolimus—Nausea—Lisinopril—dilated cardiomyopathy	0.000651	0.000988	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.00065	0.00191	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000648	0.0019	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000647	0.0019	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000633	0.00186	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000633	0.00186	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000625	0.00183	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000608	0.00178	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000608	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000608	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000603	0.00177	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000598	0.00175	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000595	0.00174	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000539	0.00158	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.0005	0.00147	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000479	0.0014	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000475	0.00139	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000474	0.00139	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000471	0.00138	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.00045	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000448	0.00131	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000448	0.00131	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000446	0.00131	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000443	0.0013	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000437	0.00128	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000426	0.00125	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000421	0.00124	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000421	0.00124	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000417	0.00122	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000417	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000417	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000414	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000413	0.00121	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.00041	0.0012	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000408	0.0012	CbGpPWpGaD
Everolimus—MTOR—Disease—NPPA—dilated cardiomyopathy	0.000394	0.00115	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000392	0.00115	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—dilated cardiomyopathy	0.000386	0.00113	CbGpPWpGaD
Everolimus—MTOR—Disease—PSEN2—dilated cardiomyopathy	0.000381	0.00112	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000379	0.00111	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD36—dilated cardiomyopathy	0.000378	0.00111	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000369	0.00108	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000363	0.00107	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RAC1—dilated cardiomyopathy	0.000356	0.00105	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000342	0.001	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RAC1—dilated cardiomyopathy	0.000341	0.000999	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000324	0.00095	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000307	0.000901	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000284	0.000833	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000267	0.000783	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000264	0.000775	CbGpPWpGaD
Everolimus—MTOR—Immune System—ITGB1—dilated cardiomyopathy	0.000258	0.000757	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000239	0.0007	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000237	0.000695	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000237	0.000695	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RAF1—dilated cardiomyopathy	0.000236	0.000693	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000228	0.000669	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000227	0.000665	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RAF1—dilated cardiomyopathy	0.000226	0.000663	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00022	0.000646	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD36—dilated cardiomyopathy	0.00022	0.000646	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000213	0.000626	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAC1—dilated cardiomyopathy	0.000208	0.000609	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000201	0.000589	CbGpPWpGaD
Everolimus—MTOR—Disease—RAC1—dilated cardiomyopathy	0.000192	0.000562	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000189	0.000554	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000182	0.000534	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000173	0.000507	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000171	0.000501	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—dilated cardiomyopathy	0.000162	0.000475	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000158	0.000464	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—dilated cardiomyopathy	0.000156	0.000456	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—dilated cardiomyopathy	0.000155	0.000454	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000149	0.000436	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAF1—dilated cardiomyopathy	0.000138	0.000404	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000134	0.000394	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—dilated cardiomyopathy	0.000128	0.000376	CbGpPWpGaD
Everolimus—MTOR—Disease—RAF1—dilated cardiomyopathy	0.000127	0.000373	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000109	0.000318	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—dilated cardiomyopathy	9.44e-05	0.000277	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAF1—dilated cardiomyopathy	8.9e-05	0.000261	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—dilated cardiomyopathy	8.72e-05	0.000256	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—dilated cardiomyopathy	6.1e-05	0.000179	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.64e-05	0.000136	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.52e-05	0.000132	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	4.07e-05	0.000119	CbGpPWpGaD
